To facilitate a systematic study of chemoresistance across diverse classes of anticancer drug candidates, we performed correlation analyses between cytotoxic drug potency and gene expression in 60 tumor cell lines (NCI-60; NCI-National Cancer Institute). Ellipticine analogs displayed a range of correlation coefficients (r) with MDR1 (ABCB1, encoding multidrug resistance (MDR) protein MDR1 or P-glycoprotein). To determine MDR1 interactions of five ellipticines with diverse MDR1-r values, we employed MDR1-transport and cytotoxicity assays, using MDR1 inhibitors and siRNA-mediated MDR1 downregulation, in MDR1-overexpressing cells. Ellipticines with negative correlations-indicative of MDR1-mediated resistance-were shown to be MDR1 substrates, whereas those with neutral or positive correlations served as MDR1 inhibitors, which escape MDR1-mediated chemoresistance. Correlation with additional genes in the NCI-60 confirmed topoisomerases as ellipticine targets, but suggested distinct mechanisms of action and chemoresistance among them, providing a guide for selecting optimal drug candidates.
INTRODUCTION
Chemoresistance is a main obstacle to successful cancer chemotherapy. A systematic approach in the design of new anticancer drugs is needed to select drug candidates among a series of congeners that avoid chemoresistance mechanisms. Correlation of gene expression in cancer tissues with cytotoxic drug potency represents a useful tool in the study of chemoresistance. 1 Using cDNA microarrays, Scherf et al 2 have correlated gene expression in a panel of 60 human tumor cell lines (NCI-60; NCI-National Cancer Institute) to growth inhibitory potencies of anticancer drugs with known mechanism of action. High expression of a given gene in drug-sensitive cell lines yields a positive correlation, whereas high expression in resistant cells gives negative correlations. For example, DPYD (dihydropyrimidine dehydrogenase) expression was negatively correlated with 5-fluorouracil (5-FU) activity, which is consistent with previous results that high DPYD levels-involved in the catabolism of pyrimidines and 5-FU-decrease exposure of cells to the active phosphorylated metabolites of 5-FU. 2 As an extension of this study, our laboratory has previously used 70-mer oligonucleotide arrays to analyze gene expression, in the NCI-60 cell panel, of membrane transporters and channels, which govern cellular influx and efflux of ions, nutrients, and drugs. Correlating gene expression with the potencies of 119 standard anticancer drugs identified known drug-transporter interactions and suggested novel ones. 3 In particular, correlation analysis of MDR1 (or ABCB1, encoding the multiple drug resistance protein 1 (MDR1), or P-glycoprotein (Pgp)) mRNA levels and drug potencies in the NCI-60 panel sensitively identified all known MDR1 substrates among the 119 drugs, and Baker'santifol and a geldanamycin analog as novel substrates. Use of RNA interference (or small interfering RNA, siRNA) to reduce MDR1 mRNA levels in multidrug resistant cell lines, or application of MDR1 inhibitors, increased sensitivity to these two drugs, as expected for MDR1 substrates. 3 For validated transporter genes such as MDR1, the gene-drug correlations enable one to search for additional likely substrates from a much larger database containing the potencies of 460 000 drugs against the NCI-60 cell panel (available from the NCI Developmental Therapeutics program (http://dtp.nci.nih.gov)). Here, we correlated MDR1 gene expression data generated by an oligonucleotide microarray 3 with potency of 7466 compounds (NCI 7.5K) that had been tested against the NCI-60 drug screening panel.
We selected MDR1 for further study because: (1) MDR1 shows a wide range of strong correlations with chemosensitivity to cytotoxic compounds; (2) MDR1 expression conveys chemoresistance to its substrates by decreased accumulation in target cells through active drug efflux; 4, 5 (3) numerous compounds of dissimilar structures can serve as MDR1 substrates; [4] [5] [6] [7] (4) use of MDR1-specific inhibitors, such as cyclosporin A and verapamil, can suppress MDR1-related resistance, 8, 9 but clinical use of these inhibitors remains problematic. Therefore, avoidance of MDR1-mediated chemoresistance is desirable.
In the present study, we focused on the ellipticines because of their potent anticancer activity 10 and broad range of correlation coefficients with MDR1 gene expression across the members of the class. Among five ellipticines selected for further analysis, those showing negative correlations were found to be MDR1 substrates, whereas those showing no or positive correlations appear to function as inhibitors. In addition, further drug-gene correlation analysis revealed differences in mechanisms of action and mode of resistance for the ellipticines, thereby distinguishing closely related compounds. This study provides an approach for associating groups of potentially novel compound classes with relevant gene families, followed by experimental validation. It can be applied to other genes or gene families for the purpose of mining available information on structure-activity relationships and gene expression, to guide the selection of candidate anticancer drugs.
RESULTS

Selection of MDR1 as an Initial Gene Probe
Gene expression was measured with a microarray using 756 oligonucleotide probes (70-mers) targeted to gene families encoding drug transporters, ion exchangers and ion channels, and a few additional gene families, for example, metalloproteases. 3 Analysis of mRNA prepared from NCI-60 cancer cell lines resulted in a database designed to study entry and extrusion of drugs across the cell membrane, and intracellular compartments, a process critical to drug response. The resulting gene expression profiles were correlated with cytotoxic potencies of the NCI 7.5K compound database. The distribution of the 756 Â 7500 Pearson's correlation coefficients is slightly skewed at the negative extreme end (data not shown). At 2.5% error rate at both tails, the correlation coefficients are significant if greater than 0.29 or lower than À0.28.
For each gene, correlations with all 7466 compound activities were analyzed for outliers at both extremes. The selected gene outliers, listed in Supplementary Table 1 , belong to various gene families: 60% transporters, 21% channels, and 6% membrane metalloproteases (eg, ADAM, MMP, and other families). Among these genes, MDR1 showed the highest number of outliers (273) and gave the largest spread in the correlations between minimum (À0.94) and maximum (0.69) values. The wide range and strong correlations indicate that MDR1 may be a good candidate gene for probing compound classes for potential substrates or inhibitors. Substrates with high negative correlations are expected to be sensitive to MDR1 expression as a significant resistance factor.
Identification of the Ellipticine Class from MDR1
Correlations Taking MDR1 as a probe, we searched for correlated compound classes, defined by similar chemical structures, in the NCI 7.5K. anticancer agent database. To analyze the structure-activity relationships with MDR1 expression, we clustered the NCI 7.5K set by agglomerative clustering using the complete linkage method.
11,12 Table 1 shows the 14 compound classes containing 15 or more compounds showing high correlation with MDR1 with extreme z-scores (zX3.5 or zpÀ3.5) (z-scores are a measure of the strength of the correlation). Several classes containing known MDR1 substrates exhibited strong negative correlations: taxols (class 14), geldanamycin analogs (class 8), anthracyclines (class 9), and analogs of halacanthone and brutasol (class 12). At the other end of the spectrum were classes showing positive correlations with MDR1 expression. Prominent among these were a-picoline thiosemicarbazones (classes 1, 4, and 6) and analogs in which the thiourea is partially incorporated in an aromatic system (class 3). Significant positive correlations have been noted previously for MDR1; 13 however, the mechanism underlying positive correlations between MDR1 expressions and drug potency remains to be clarified.
Two classes of ellipticines (classes 7 and 13) contained compounds with either highly positive or negative correlations with MDR1. The distinguishing characteristic between these classes was the presence of a pyridinium ion, which conveys a permanent positive charge. Class 13 containing the pyridinium ion (ellipticiniums) showed strong negative Figure 1 for further studies. The ellipticiniums, NSC 155694 and 359449, have strong negative correlation with MDR1, whereas the ellipticines NSC 86715, 69187, and 338258 exhibit strong to low positive correlations. Our hypothesis is that the two ellipticiniums are substrates while the three ellipticines may not interact with, or serves as inhibitors of MDR1.
Substituent Analysis of Ellipticine Analogs
To study the entire ellipticine subset, we selected all related compounds from the NCI 7.5K set that contain the substructure closely related to 5-methyl-pyrido [4,3-b] carbazole, representing the core of the ellipticine moiety. This resulted in a subset of 61 compounds which were examined for substituent effects (Table 2) . In most cases, the pyridine ring is aromatic (ie, pyridine), but there are also a small number of 1,2-dihydropyridines. Most variation occurs at N 2 and C 9 , and these are shown in columns labeled R 1 and R 2 , respectively. Minor variation also occurs at C 1 , N 6 and C
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. The main substituent effect on MDR1 correlations is at N 2 . The 31 ellipticinium compounds with an N 2 -alkyl substituent show strong negative correlations with MDR1 with a mean of À0.36 and range from À0.87 to 0.04. To corroborate compound-MDR1 correlations, we also calculated the difference in cytotoxic potency (GI 50 value) between cell lines NCI/ADR-RES (highly expressing MDR1) and OVCAR-8 for each compound. OVCAR-8 cells express low levels of MDR1, while the two cell lines are otherwise similar in overall gene expression pattern; see Figure 2 of Scherf et al. 2 The ellipticinium compounds are on average approximately 20 times less potent against NCI/ADR-RES than OVCAR-8, with DGI 50 values ranging from À0.13 to À2.65. In contrast, the 28 ellipticines with a neutral pyridine There is a significant, but secondary, effect on MDR1 correlations from the substituent at C 9 . In both series, the hydrogen substituent tends to yield more extreme MDR1 correlation values, more negative for ellipticinium compounds and more positive for ellipticines, suggesting more avid interaction with MDR1. Values for C 9 alkoxy groups in both series tend to be close to zero.
The ellipticine NSC 86715 with a high positive correlation with MDR1 (r ¼ 0.60) differs from most ellipticines through a bulky substituent at C 1 adjacent to the pyridine N. Several other ellipticines also have bulky C 1 substituents and positive MDR1 correlations ranging from 0.22 to 0.38.
Four ellipticinium compounds behave more like ellipticines, with MDR1 correlations and DGI 50 values close to zero. All four ellipticinium compounds contain an alkyl-CO 2 -CH 2 -fragment on the pyridine N 2 . In an earlier study, Shi et al 10 had observed similar anomalous behavior for these compounds. The authors proposed a mechanism by which the side chain can decompose under the culture conditions to the corresponding ellipticine. This involves ester hydrolysis followed by collapse of the hemiaminal. Our correlation data are consistent with this proposal. Freq gives the number of compounds with each substituent combination. The right four columns are pairs of mean and z-score for compound correlations with MDR1 and for the difference in GI 50 value between cell lines NCI/ADR-RES and OVCAR-8. For each compound set corresponding to a substituent combination, the z-score was computed relative to the 61 ellipticine set.
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Comparison of Ellipticine Analogs against NCI 'Standard Agent' Database
Comparison of the activity patterns of cytotoxic compounds across the NCI-60 panel can reveal details of their mechanism of action and resistance. 14 We next analyzed the five ellipticine analogs (Figure 1 ) using the COMPARE program, to identify agents with similar activity patterns across the NCI-60 panel.
14 Shown in Table 3 , one of the novel MDR1 inhibitors, the ellipticine NSC 86715 (see experiments below), did not correlate with any compound in the NCI 'Standard Agent' database (all correlation coefficients o0.45), suggesting that NSC 86715 may act by a mechanism different from that of any of the standard agents. Both of the other two hypothesized MDR1 inhibitors, NSC 338258 and 69187, showed high Pearson's correlation coefficient against pyrazofurin and N-N-dibenzyl-daunomycin, suggesting that they may act as RNA synthesis inhibitor or DNA binder. This is in agreement with previous studies on ellipticine derivatives. 15, 16 The hypothesized MDR1 substrates, the ellipticiniums NSC 359449 and NSC 155694, were highly correlated with known MDR1 substrates, bisantrene, daunarubicin or paclitaxel. This correlation suggests that these compounds may have the same mode of MDR1-mediated drug resistance regardless of the mechanism of action. Within the NCI-60, MDR1 overexpression represents a dominant resistance mechanism in cells where the gene is highly expressed. Even though ellipticines have been shown to inhibit topoisomerases, they failed to cluster with many of the known topoisomerase inhibitors.
Analysis of Mechanism of Action and Resistance using a Genomewide Gene-drug Correlation Database
To further differentiate the mechanisms of action of ellipticiniums (NSC 359449 and 155694) and ellipticines (NSC 86715, 69187, and 338258), we queried a genomewide gene expression database of the NCI-60. Correlation coefficients were calculated between compound potency and expression of 12 626 genes in the U95Av2 probe set (http:// dtp.nci.nih.gov/mtargets/madownload.html), ranging from 0.81 to À0.82, with the average centered at À0.006 (data not shown). To limit the scope of the analysis, we selected 1926 genes with Pearson's correlation coefficients for at least one compound greater than 0.4 or less than À0.4. These genes were then clustered using correlations with the five compounds as descriptors (Supplementary Figure 1) . Two clearly separated gene clusters defined the ellipticines NSC 69187 and 338258; a cluster of 845 genes negatively correlated with compound activities and 1081 genes with positive correlations. MDR1 belongs to a small group of genes in which only NSC 86715 correlated positively and four other ellipticine analogs correlated either strongly negatively or were neutral. This small group also includes APG-1 (heat shock protein), TSTA3 (tissue specific transplantation antigen P35B), CYC1 (cytochrome c-1), HOXA11 (homebox A11), ARF1 (ADP-ribosylation factor 1), SIAHBP1 (fuse-binding protein-interacting repressor), PROCR (EPCR, endothelial protein C receptor), TSSC3 (tumor suppressing subtransferable candidate 3), and RAB1A (member RAS oncogene family). These gene-drug correlations confirm substantial differences between each compound, similar to what was deduced from the COMPARE analysis (gene-cell correlations using cytotoxic potency against the NCI-60 as descriptors). Moreover, the results identify NSC86715 as having a distinct pattern of correlations from the other derivatives, indicative of a different mechanism of action.
Grouping of genes using the Pearson correlation coefficients against the ellipticine classes was further explored by principal component analysis. The five ellipticine compounds were differentiated by three factors, which described 94% of variations in the data. Factor 1 consists of the two ellipticiniums (NSC 69187 and 338258) and factor 3 groups two ellipticines, NSC 155694 and 359449. Surprisingly, factor 2 groups the ellipticines NSC 86715 and NSC-359449. The two compounds exhibited opposite associations on the same set of genes, suggesting that their cytotoxic potency may be related to the same resistance (or cell survival) mechanism. The biplot rays in Figure 2 illustrate the proximity of these compounds; the angle between the two ellipticins (in factor 2) is almost 180 o , while the other two nonsubstrates (in factor 1) are the most closely MOA: the mechanism of action or the mechanism of resistance derived from known mechanism of the target compounds identified from the NCI standard compound database.
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grouped. This analysis also supports the notion that the two substrates may be only marginally related in terms of their mechanism of action and chemoresistance.
Shown in Supplementary Tables 2 and 3 , factors 1 and 2 encompass topoisomerases as prominent members, a known target for the ellipticinium class. 17 Also found in this gene cluster are numerous genes encoding transcription factors, growth factors, lymphocyte-specific protein tyrosine kinase, and zinc-finger proteins. Clustering and principal component analyses of genes using ellipticine compounds as probes refines the grouping of the ellipticine compound classes that may follow different mechanisms of action and resistance.
Validation of MDR1-compound Correlations using MDR1 Inhibitor and MDR1-specific siRNA To test whether the ellipticine analogs with negative MDR1 correlations are potential MDR1 substrates, we first performed cytotoxicity studies. NCI/ADR-RES cells express high MDR1 levels and show chemoresistance to MDR1 substrates. 3 Similarly, K562/DOX cells are resistant to doxorubicin due to MDR1 overexpression. 18 These cell lines were treated with increasing concentrations of ellipticines, with and without the presence of the MDR1-antagonist cyclosporin A (CsA). Alternatively, NCI/ADR-RES cells were treated with MDR1-specific siRNA, 3 using nonsilencing siRNA as the negative control. Shown in Table 4 , both CsA and MDR1 siRNA sensitized the cells to compounds negatively correlated with MDR1, that is, NSC 155694 and NSC 359449, providing evidence that these compounds are MDR1 substrates. For NSC 155694 and NSC 359449, respectively, the shift in potency was 18-and 79-fold after CsA treatment, and 3.8-and 2.1-fold after siRNA transfection in NCI/ADR-RES cells. The shift was 19-and 8.6-fold, respectively, after CsA treatment of K562/DOX cells. We used 10 mM verapamil to replace CsA for the experiment and obtained similar results. Figure 3 shows the growth inhibition curves for NCI/ADR-RES. Although both CsA and siRNA reversed the resistance to NSC 155694 and NSC 359449, siRNA treatment was only partially effective, presumably because transient transfection of siRNA failed to fully suppress MDR1 expression in all the cells. However, the finding that both siRNA and MDR1-inhibitors caused detectable sensitization indicated that siRNA can be suitable for validation of drug-gene interactions when specific inhibitors are not available.
In contrast to the results with NSC 155694 and NSC 359449, treatment of NCI/ADR-RES and K562/DOX cells with CsA or siRNA had no impact on potency of the other three ellipticines, NSC 86715, NSC 69187 and NSC 338258, which did not correlate negatively with MDR1 expression (Table 4, Figure 3 ). The mechanism underlying the positive correlation of NSC 86715 with MDR1 remains to be clarified. Failure of CsA to affect the potency of NSC 86715 indicates that drug potency is independent of MDR1 transport activity. We further compared the cytotoxic IC 50 value of NSC 86715 in K562/DOX and its parental cells K562, which do not express detectable MDR1 levels. Again, there was no difference in the IC 50 (data not shown) . For NSC 69187 and 338258, which have negligible Pearson's correlation coefficients with MDR1, CsA or siRNA treatment slightly decreased their potency (Table 4) . Moreover, NSC 69187 was more active against K562/DOX than K562, whereas for NSC 338258 the activity was the same (data not shown). This indicates that they are poor substrates for MDR1. For these two ellipticines, MDR1 could play a role independent of drug efflux; for example, high expression could result in changes of membrane potentials 19 or enhanced apoptosis after drug treatment. 20 We also studied the effects of CsA on the two ellipticines in KM12 and OVCAR-8 cells, which do not express detectable MDR1. For both compounds, the potency was decreased by the addition of 5 mM CsA in each of the two cell lines, suggesting that the interactions of NSC 69187 or 338258 with CsA may be unrelated to MDR1 expression, as previously reported. 21 We conclude that the three ellipticine analogs are not MDR1 substrates. 
Inhibition of MDR1-mediated Efflux of Fluorescent Markers
We tested the ellipticines for ability to inhibit MDR1-mediated efflux from MDR cells, using rhodamine-123 (R-123) and daunorubicin (DNR) as fluorescent substrates. 22 Inhibition of efflux increases intracellular fluorescence intensity, measured by flow cytometry. CsA was used as positive control at 10 mM, which maximally inactivated MDR1 efflux in our test (data not shown). The IC 50 values of the test compounds (half-maximum inhibition of marker efflux) were determined from inhibition curves at different inhibitor concentrations ( Figure 4 , Table 5 ). All compounds tested except NSC 155694 inhibited MDR1-mediated efflux of DNR or R-123 in a dose-dependent fashion ( Figure 4 , Table 5 ). NSC 359449, the putative MDR1-substrate, increased intracellular DNR accumulation to a smaller extent with a high IC 50 (Table 5 ) compared to the other ellipticines (see below), indicating that it is an MDR1 substrate exerting competitive inhibition. The ellipticine NSC 155694 failed to increase the DNR accumulation even at 800 mM. This is consistent with previous observations that MDR1 substrates often show low inhibitory potency. 21 Although not MDR1 substrates, the three ellipticine derivatives lacking negative correlation with MDR1 strongly enhanced the accumulation of both R-123 and DNR ( Table 5 , Figure 4 , and Supplementary Figure 2) . The ellipticine NSC 86715 yielded the highest inhibition with R-123 as marker (143% relative to 10 mM CsA), while NSC 338258 caused the highest DNR accumulation (157% relative to 10 mM CsA). NSC-69187 achieved 71% inhibition of R-123 efflux relative to CsA. Differences in maximal inhibition may arise as a result of multiple substrate binding sites on MDR1, one being selective for R-123, 23 prompting the use of both DNR and R-123 as the fluorescent markers, 22 and yielding different binding parameters between DNR and R-123. 24 In combination with the cytotoxicity results, these results indicate that the three ellipticines are inhibitors of MDR1, but may differ in their mode of binding.
Effect of Ellipticine NSC 86715 on Paclitaxel Cytotoxicity Against K562/DOX and NCI/ADR-RES
To test drug interactions with the MDR1-substrate, paclitaxel, K562/DOX and NCI/ADR-RES cells were incubated with increasing concentration of paclitaxel in the absence or presence of NSC 86715. Significantly enhanced sensitivity to paclitaxel was observed. The shift in potency was 7.471.6-and 103741-fold after NSC 86715 treatment in K562/DOX (1.25 mM), and in NCI/ADR-RES cells (2.5 mM), respectively. Because the ellipticines NSC 69187 and 338258 are already toxic to the cells at the concentrations needed to achieve efflux inhibition, we were unable to quantitate their interaction with paclitaxel at MDR1.
DISCUSSION
In this study, we used chemoinformatics to identify functionally related compound classes, and characterize compounds within a given class. Using correlations between gene expression and cytotoxic potency, we selected MDR1 as an example for identifying substrates and inhibitors of MDR1. This approach can be applied to other genes or genes in a specific pathway (or family), in particular, transporter genes because of the direct relationship between transporter and substrate. 3 Because of a broad range of MDR1-compound correlations, we chose the ellipticine derivatives for detailed analysis of MDR1 transport, and subsequently, for a search of genes related to the mode of actions of compounds within this class.
Combining chemoinformatics and experimental functional assays, the initial step identifies the relationships between gene expression and activity of compound classes that were grouped by substructural similarity, using an analytical tool termed SAT. 25, 26 Compound classes that are strongly correlated with the expression pattern of a candidate gene are selected for study by functional assays, to validate the calculated gene-compound correlation. This involved changes in cytotoxicity in the presence or absence of specific inhibitors or siRNA-mediated gene knockdown technology, providing insight useful to drug design and selection of therapy. Furthermore, selected members of the compound class can be used as molecular probes to identify additional compound-gene correlations, thereby identifying genes for which expression levels correlate strongly with structural features of particular compounds. Therefore, this pharmacogenomics approach has the potential to accelerate the process of drug discovery and also shed light on molecular mechanisms of novel compounds.
In this study, we identified MDR1 substrates through high negative correlation between MDR1 expression and cellular sensitivity to a large numbers of compounds, which had been tested against the NCI-60 anticancer drug-screening panel. Among numerous compounds showing significant correlations with MDR1 expression (Table 1) , many are known MDR1 substrates, for example, taxols and anthracyclines. This study focuses on two classes of ellipticines, showing both significant positive and negative correlations with MDR1. While the entire set of ellipticine derivatives was used for analysis of structure-activity relationships, five ellipticines shown in Figure 1 were selected for detailed study. The two ellipticiniums were identified as MDR1 substrates, both by negative correlations between gene expression and protein levels with drug potency, and with the use of R-123 efflux as reported previously. 6, 7, 27 These studies combined validate the use of correlation analysis to predict MDR1 substrates. One of the two ellipticinium MDR1-substrates (NSC 359449) was able to inhibit MDR1-mediated efflux of fluorescent markers, whereas NSC 155694 was not. This is consistent with the notion that efficiently transported MDR1-substrates can have poor inhibitory potency. 21 In contrast, the three ellipticines significantly blocked R-123 efflux. A compound has been defined as MDR1 substrate if cytotoxicity increases X4-fold by adding CsA, and as MDR1 inhibitor if inhibition of efflux increases R-123 accumulation X4-fold. 21 In the present study, two ellipticiniums met the criteria as substrate, and three ellipticines met the criteria of inhibitor. Among the three inhibitors, NSC 86715 appears to block the MDR1 efflux by a different mechanism than the other two, based on compound-compound and compound-gene correlations. The primary structural factor discriminating between MDR1 substrates and nonsubstrates in the ellipticine class is substitution at N 2 . Ellipticiniums with alkyl substituents at N 2 show strong negative correlations with expression of MDR1 and much lower cytotoxicity toward NCI/ADR-RES with high MDR1-expression, compared with the similar cell line OVCAR-8 with low MDR1-levels. Ellipticines that are unsubstituted at N 2 do not show these differences. Furthermore, while NSC 69187 and 155694 are structurally similar, their biological activities differ. To negate the effects of MDR1 on compound potency across the NCI-60 panel, we ignored the three high-expressing MDR1-cell lines NCI/ ADR-RES, HCT-15, and UO-31, and recalculated the correlations between compound activities for the five ellipticines. Whereas NSC 69187 and NSC 155694 are dissimilar, having a low correlation of 0.26, NSC 69187 and NSC 338258 ( Figure 1 ) resemble each other (correlation 0.76), their potencies depending on a number of common highly correlated genes (see also Figure 2 and Supplementary Tables  2 and 3 ). Thus, while N 2 substitution is a critical determinant for interaction with MDR1, the overall effect on biological activity is more complex.
Because ellipticine drugs have been reported to target topoisomerases, we calculated correlations between the expression patterns of topoisomerases and compound potencies of the full NCI 7.5K set, again ignoring the three primary MDR1 cell lines. Both NSC 69187 and NSC 338258 show strong correlations with Top2, while NSC 338258 has the highest correlation (0.72) of 7466 compounds with the expression of Top1 (Accession Number GC32999). In contrast, the topoisomerase inhibitor camptothecin (NSC 94600) was poorly correlated with Top 1 (0.07). Understanding the biological basis for these discrepancies requires further study, but our results confirm that some ellipticines appear to act as topoisomerase inhibitors, while they differ substantively from other known topoisomerase inhibitors in their gene correlation profile.
Searching for genes that are significantly correlated with these ellipticine classes from a larger genomewide database resulted in gene families that may serve to differentiate their mode of action. Correlated genes encode topoisomerases, BCL2, zinc-finger proteins, phosphoinositol kinases, protein tyrosine phosphatases, heat shock protein transcription factors, and growth factors. Further studies are required to address the significance of these correlations and their potential use in selecting optimal drug candidates.
In summary, we have developed a chemoinformatics approach to drug discovery. We have correlated gene expression to compound activity patterns in the 60 NCI cancer cell lines and selected MDR1 and ellipticine analogs as a test case. Whereas two ellipticiums studied were MDR1-substrates, three other ellipticines were found to be inhibitors-clearly a desirable property for a drug candidate. Further correlation analysis involving large gene expression data in the NCI-60 indicated different mechanisms of action and mode of resistance for these compounds. This approach provide a general path to selecting optimal drug candidates and identifying chemoresistance genes.
INFORMATICS METHODS Compound Activity Database for NCI-60 Cell Lines
To analyze gene expression-chemical structure relationships, the September 2003 release of the National Cancer Institute's (NCI) antitumor drug screening database was used. The data were obtained from the NCI's Developmental Therapeutics Program (DTP) website (Human Tumor Cell Line Screen: http://dtp.nci.nih.gov/docs/cancer/cancer_da-ta.html) containing nonconfidential screening results and chemical structural data from the NCI's Developmental Therapeutics Program. For each compound and cell line, growth inhibition after 48 h of drug treatment had been assessed from changes in total cellular protein using a sulforhodamine B assay. 14, 28 The data provide GI 50 values for each compound-cell line pair (log 10 (1/C); C, the concentration causing 50% growth inhibition). From these data, we selected a subset of 7466 compounds (denoted NCI 7.5K) that had been tested two or more times for at least 30 of the NCI-60 cell lines.
Gene Expression Databases of NCI-60
Gene expression profiles were measured for the NCI-60 panel using 70-mer based oligonucleotide microarrays containing 756 probes. 3 Probes were selected to detect mRNAs for a majority of transporters, ion exchangers, ion channels, and other unrelated gene families. A second database, the Novartis microarray data set, was also employed for a broad genomewide screen. This data set is available at NCI DTP website (http://dtp.nci.nih.gov/ mtargets/download.html, March 2004). The Novartis set contains the average of triplicate expression measurements for 59 NCI cell lines based on 12 626 oligonucleotide probes from Affymetrix U95Av2 arrays. Gene assignments are based on Unigene Build #166.
Correlation of Gene Expression Profiles with Compound Activity Patterns
Pearson's correlation coefficients were calculated to correlate gene expression profiles with patterns of compound activities across the NCI-60.
where s A i is the activity standard deviation of ith compound, s T j is expression standard deviation of jth gene, and s A i T j is covariance. Correlations were not calculated if more than one-third of the data points are missing for a given genecompound pair; the handling of missing values was described previously. 26 Complete correlation analysis was performed for expression profiles measured with 756 70-mer oligonucleotide and 12 626 U95Av2 oligo-probe sets against the NCI-60 activities of 7466 compound activities. From the distributions of the Pearson correlation coefficients, two-tail threshold coefficients at 2.5% error rate were determined.
Mining Genes and Gene Families
Conventional outlier analysis was used to select significantly correlated genes from the 70-mer oligonucleotide microarray. Genes were considered outliers if the gene-compound correlations were outside of the box-plot whiskers. A whisker distance is 1.5 IQR (interquartile range), which is the distance between 25 and 75% of the data range. The outlier genes (Supplementary Table 1) were prioritized by the large difference between the minimum and maximum correlations across the 7446 compounds per given gene.
To differentiate gene-drug correlation patterns among the compounds of interest (ellipticines in this case), genes were clustered by agglomerative nesting as well as principal component analysis (PCA) 29 methods using the genecompound correlations as descriptors and genes as observations. Three factors from PCA were rotated so that loadings could be interpreted. The rotated scores were sorted to select influential genes. In the case of the Novartis genome database, genes were preselected based on significant compound correlations.
Mining Structural Compound Features
To evaluate structure-activity relationships on the basis of correlated gene expression profiles, we clustered the NCI-60 7.5K compound set by agglomerative nesting using the complete linkage method. 11, 12 The compound distance matrix-a measure of similarities or differences in chemical structures-was calculated using the Tanimoto coefficient based on the Leadscopet feature set. 11 Clustering resulted in 1856 classes at the threshold distance for cluster linkage of 0.7. The largest class contained 56 doxorubicin analogs, and 486 compounds were in singleton classes.
For gene-compound correlations, Pearson's correlation coefficient between the compound activity pattern and a gene expression profile was calculated as described in Blower et al. 26 Furthermore, for each class we calculated the mean compound class-gene correlation. To statistically compare the correlation of individual compound class and gene with that of mean compound-gene correlation for the full NCI 7.5K set, z-score was calculated according to the following equation:
where x 1 , x 0 are the mean activities of the subset and full set, respectively, n 1 and n 0 are the set sizes and s 0 2 is the sample variance of the full set.
EXPERIMENTAL METHODS AND MATERIALS Compounds
The five ellipticine derivatives were obtained from the Developmental Therapeutics Program at NCI (National Institutes of Health). Daunorubicin (DNR) and Cyclosporin A (CsA) were purchased from Sigma Chemical Co. (St Louis, MO, USA). R-123 was purchased from Molecular Probes (Eugene, OR, USA).
Cell Culture
The cell lines were cultured in RPMI 1640 medium containing 5 mM L-glutamine, supplemented with 10% fetal bovine serum (FBS), 100 U/ml sodium penicillin G and 100 mg/ml streptomycin. Cells were grown in tissue culture flasks at 371C in a 5% CO 2 atmosphere. The NCI/ADR-RES and K562 cell lines comprising the anticancer drug screen were obtained and processed as described previously.
30 K562/ Dox cell line (a gift from JP Marie, INSERM, E9912, University of Paris, France) was obtained by in vitro passaging of K562 in progressively increasing doses of DNR, 18 cultured as the other cell lines, and retreated with 0.1 mM doxorubicin once a month.
SRB Cytotoxicity Assay
Drug potency of NCI/ADR-RES (adherent cells) was tested using a proliferation assay with sulforhodamine B (SRB), a protein-binding reagent. 31 In each experiment, 3000-4000 cells per well were seeded in 96-well plates and incubated for 24 h. Anticancer drugs were added in a dilution series in three replicated wells for 4 days. To determine IC 50 values, the absorbance of control cells without drug was set at 1. Dose-response curves were plotted using Prism software (San Diego, CA, USA). Each experiment was performed independently at least twice. Student's t-test was used to determine the degree of significance. To study the effect of an MDR1 inhibitor, 5 mM CsA was added to the cells 20 min before and during exposure to drugs, and the plates were incubated for 4 days.
XTT Cytotoxicity Assay
The chemosensitivity of K562 and K562/DOX cells (cells in suspension) was assessed with the XTT assay (sodium 3 0 -[1-(phenylaminocarbonyl)-3,4-tetrazolium]-bis (4-methoxy-6-nitro) benzene sulfonic acid hydrate) (Sigma). Cells were seeded with a density of 5000 cells/well in 96-well plates in 100 ml medium and incubated for 24 h before exposure to graded concentration of each drug for 3 days.
siRNA-mediated Downregulation of MDR1 Gene Expression siRNA duplexes for MDR1 were chemically synthesized by QIAGEN Inc. (Valencia, CA, USA). The target sequence was 5 0 -AAG CGA AGC AGT GGT TCA GGT-3 0 , beginning from nt 2113 of the MDR1 mRNA sequence NM_000927, as recommended (http://www1.qiagen.com/products/genesilencing/ cancersirnaset.aspx). Chemically synthesized mock siRNA (fluorescein-labeled, nonsilencing) was also purchased from QIAGEN. Transfection was performed with TransMessenger Transfection Reagent (QIAGEN). Cancer cells were transfected with 0.3 mM siRNA. For RNA extraction, cells were harvested 48 h after transfection. To measure cytotoxic drug potency, cells grown in six-well plates were subcultured into 96-well plates 24 h after transfection.
Flow Cytometry
The capacity of a compound to inhibit MDR1-mediated efflux from K562/DOX cells, was measured by flow cytometry. 22 The cells were centrifuged (50 g for 5 min) at room temperature and resuspended in RPMI 1640 medium with 10% FBS (371C) at a concentration of 6 000 000 cells/ml. Aliquots (50 ml) of the cell suspension were transferred to tubes containing 1.95 ml of the incubation media containing DNR or R-123. The cells were incubated in the presence of absence of test drugs in RPMI 1640 medium with 10% FBS with 5 mM of DNR for 50 min, or with 1 mg/ml of R-123 for 30 min at 371C. After centrifugation (50 g for 5 min at 41C) and removal of supernatant, cold PBS was added to each tube, and cell suspension was transferred to FACS tubes, which were placed on ice (less than 1 h) until analysis.
Flow cytometry was performed with a Becton-Dickinson FACS Calibur (San Jose, CA, USA) equipped with an ultraviolet argon laser (excitation at 488 nm, emission at 530/30 nm for R-123 and 585/42 nm for DNR). Analysis was based on acquisition of data from 10 000 cells. Log fluorescence intensities of individual cells were recorded as histograms. The median fluorescence intensity of 10 000 cells was used for analysis. CsA (10 mM affording maximal inhibition of MDR1-mediated efflux of DNR and R-123 in K562/DOX) served as a positive control and for normalization of the results across experiments. The % inhibition of fluorescent dye efflux was calculated as follows:
Relative fluorescence ¼ Fluorescence median of a sample Fluorescence median of 10mM CsA Â100
